Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Defines Good Review Management; No Data In Labeling Negotiations

Executive Summary

Last-minute labeling negotiations are not an appropriate time for presentation of additional data by NDA sponsors, FDA said in a draft guidance on review practices
Advertisement

Related Content

Good Review Management Guidance To Be Tested By “Root Causes” Analysis
Good Review Management Guidance To Be Tested By “Root Causes” Analysis
FDA Finalizing Review Principles Guidance; Complete Submissions Urged
FDA Finalizing Review Principles Guidance; Complete Submissions Urged
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
PhRMA Feels Deadline Pressure, Reminds FDA Of Flexibility In PDUFA Goals
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
FDA Multi-Cycle Product Review Analysis To Begin In Fiscal 2004
PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
Advertisement
UsernamePublicRestriction

Register

PS042191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel